Pharmafile Logo
Pharmafocus logo
Advanced Search

Celgene

Showing 15 posts of 128 posts found.

michael_zaiac

Celgene appoints European haematology and oncology head

May 7, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Michael Zaiac

Swiss-based Celgene International Sàrl has appointed Michael Zaiac to the position of vice president of medical affairs for its European haematology …

Appointment
astrazeneca image

AstraZeneca looks to oncology match-ups to boost sales

April 24, 2015
Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor

AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …

News
michael_w

Celgene appoints former Cubist chief executive

April 20, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, cubist, michael bonney

Celgene has elected pharma veteran Michael Bonney to join its board of directors. Bonney served as chief executive and board …

Appointment
NICE image

NICE decisions made on Bayer, Celgene and Boehringer drugs

March 26, 2015
Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance

In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …

News

Pfizer, Novartis and Celgene among late-stage psoriasis trial advances

March 23, 2015
Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib

Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …

News
Cancer image

Precision medicine: the future of cancer treatment?

March 2, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Celgene, Precision, melanoma, oncology, underwood

There are plenty of advances in oncology treatments to be excited about – from immunotherapy to cancer vaccines and monoclonal …

Feature
Revlimid image

Celgene gets FDA licence extension for myeloma drug

February 19, 2015
Sales and Marketing Celgene, FDA, Revlimid, lenalidomide, myeloma

The FDA has given Celgene an extended licence for its multiple myeloma drug Revlimid (lenalidomid), to include people who are …

News
Celgene image

Celgene’s blood cancer pill too expensive for NHS

February 13, 2015
Sales and Marketing Celgene, NHS, NICE, Pomalidomide, imnovid, myeloma

NICE has decided not to recommend Celgene’s Imnovid for treating patients with multiple myeloma – a cancer that affects white …

News
Sam Pierce image

Celgene UK: market access is a complex business

December 15, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce

Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …

Feature
bio_wim_sep_2014

Celgene appoints new UK general manager

December 9, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Wim Souverijns

Celgene has appointed Wim Souverijns as its new vice president and general manager for UK and Ireland. Souverijns (pictured) takes …

Appointment
Celgene image

Celgene expands immunotherapy pipeline with Sutro

October 27, 2014
Research and Development, Sales and Marketing Celgene, PD-1 and PD-L1, Q3, oncology, sutro

Celgene has extended its collaboration with Sutro Biopharma and added a buyout option for the firm as the two companies …

News
Celgene image

Celgene rebuffed by NICE over cancer drug

September 9, 2014
Sales and Marketing Abraxane, Cancer, Celgene, Gemzar, NICE, gemcitabine, nab-paclitaxel

In new draft guidance NICE says that Celgene’s Abraxane (nab-paclitaxel) taken with Lilly’s Gemzar (gemcitabine) should not be funded by …

News
celgene_1_02_1

NICE won’t back Revlimid in new setting

July 31, 2014
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma

NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …

News
Rob Moore image

Working Life: Celgene’s Rob Moore

July 14, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Working Life, rob moore

How did you find your way into your current role? I joined the pharmaceutical industry almost 20 years ago with …

Feature
Celgene image

Scottish Medicines Consortium disappoints Celgene

July 8, 2014
Sales and Marketing Celgene, SMC, Scottish Medicines Consortium, imnovid, myeloma

Celgene admitted it is ‘disappointed’ with the Scottish Medicines Consortium decision not to recommend blood cancer therapy Imnovid for patients …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024